
USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$53.13M
Market Cap
-
P/E Ratio
-4
EPS
$12.15
52 Week High
$1.20
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $3.3M |
| Total Revenue | $3.3M |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$15M |
| Selling General And Administrative | $7.3M |
| Research And Development | $10M |
| Operating Expenses | $18M |
| Investment Income Net | - |
| Net Interest Income | -$708K |
| Interest Income | $254K |
| Interest Expense | $962K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $607K |
| Income Before Tax | -$11M |
| Income Tax Expense | -$788K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$11M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$10M |
| Ebitda | -$9.8M |
| Net Income | -$11M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $3.3M |
| Total Revenue | $3.3M |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$15M |
| Selling General And Administrative | $7.3M |
| Research And Development | $10M |
| Operating Expenses | $18M |
| Investment Income Net | - |
| Net Interest Income | -$708K |
| Interest Income | $254K |
| Interest Expense | $962K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $607K |
| Income Before Tax | -$11M |
| Income Tax Expense | -$788K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$11M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$10M |
| Ebitda | -$9.8M |
| Net Income | -$11M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Evaxion Biotech AS (EVAX) is a pioneering clinical-stage biopharmaceutical company based in Hørsholm, Denmark, leveraging advanced artificial intelligence to drive innovation in immunotherapy. With a strategic focus on addressing unmet medical needs in oncology, bacterial diseases, and viral infections, the company utilizes its proprietary platform to identify and develop novel therapeutic candidates. As Evaxion progresses its diverse pipeline, it aims to transform treatment paradigms and enhance patient outcomes, establishing itself as a significant force within the biotechnology industry.